CN115806885A - Preparation method of anthrax protoplast and construction method of genetic transformation system - Google Patents
Preparation method of anthrax protoplast and construction method of genetic transformation system Download PDFInfo
- Publication number
- CN115806885A CN115806885A CN202310027554.XA CN202310027554A CN115806885A CN 115806885 A CN115806885 A CN 115806885A CN 202310027554 A CN202310027554 A CN 202310027554A CN 115806885 A CN115806885 A CN 115806885A
- Authority
- CN
- China
- Prior art keywords
- anthrax
- protoplast
- solution
- present
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001938 protoplast Anatomy 0.000 title claims abstract description 154
- 241000193738 Bacillus anthracis Species 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 230000009466 transformation Effects 0.000 title claims abstract description 31
- 230000002068 genetic effect Effects 0.000 title claims abstract description 28
- 238000010276 construction Methods 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 16
- 108090000790 Enzymes Proteins 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 235000018597 common camellia Nutrition 0.000 claims description 41
- 239000002609 medium Substances 0.000 claims description 30
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 239000013612 plasmid Substances 0.000 claims description 21
- 240000001548 Camellia japonica Species 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 19
- 230000003115 biocidal effect Effects 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 13
- 229920000669 heparin Polymers 0.000 claims description 13
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 13
- 239000006166 lysate Substances 0.000 claims description 13
- 238000005336 cracking Methods 0.000 claims description 12
- 230000008929 regeneration Effects 0.000 claims description 11
- 238000011069 regeneration method Methods 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 229960001008 heparin sodium Drugs 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 244000061456 Solanum tuberosum Species 0.000 claims description 6
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 1
- 238000000197 pyrolysis Methods 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 abstract description 12
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 241000209507 Camellia Species 0.000 description 22
- 210000001124 body fluid Anatomy 0.000 description 16
- 239000010839 body fluid Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 16
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- 229940065181 bacillus anthracis Drugs 0.000 description 12
- 108010014251 Muramidase Proteins 0.000 description 11
- 102000016943 Muramidase Human genes 0.000 description 11
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 11
- 229960000274 lysozyme Drugs 0.000 description 11
- 239000004325 lysozyme Substances 0.000 description 11
- 235000010335 lysozyme Nutrition 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 239000006152 selective media Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000233866 Fungi Species 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000007071 enzymatic hydrolysis Effects 0.000 description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 3
- 240000003553 Leptospermum scoparium Species 0.000 description 3
- 235000015459 Lycium barbarum Nutrition 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000222199 Colletotrichum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- -1 casein amino acid Chemical class 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域technical field
本发明属于微生物遗传转化技术领域,具体涉及一种炭疽菌原生质体的制备方法及遗传转化体系的构建方法。The invention belongs to the technical field of microbial genetic transformation, and in particular relates to a method for preparing protoplasts of anthrax bacteria and a method for constructing a genetic transformation system.
背景技术Background technique
山茶炭疽菌为炭疽菌属(Colletotrichum)真菌,是茶树炭疽病的主要优势病原种之一,对茶树具有较高的致病性和危害。为了降低山茶炭疽菌对茶树的危害,防控茶树炭疽病,采用基因工程手段对山茶炭疽菌致病相关基因进行研究尤为重要,然而,目前对于山茶炭疽菌致病相关基因的功能分析鲜见报道,原因在于缺少稳定的山茶炭疽菌遗传转化体系,无法满足山茶炭疽菌致病相关基因功能分析的基本要求,进而迫切需要建立高效稳定的PEG介导的山茶炭疽菌遗传转化体系,为后续研究山茶炭疽菌的关键致病基因提供技术依据。Camellia anthracnose is a fungus of the genus Colletotrichum, one of the main dominant pathogenic species of tea anthracnose, and has high pathogenicity and harm to tea trees. In order to reduce the harm of camellia anthracnose to tea trees and prevent and control tea tree anthracnose, it is particularly important to use genetic engineering methods to study the pathogenicity-related genes of camellia anthracnose. However, there are few reports on the functional analysis of camellia anthracnose-related genes The reason is that there is a lack of a stable genetic transformation system of Camellia anthracnose, which cannot meet the basic requirements of the functional analysis of genes related to the pathogenicity of Camellia anthracnose, and it is urgent to establish a highly efficient and stable PEG-mediated genetic transformation system of Camellia anthracnose, which will provide a basis for the follow-up research on Camellia anthracnose The key pathogenic gene of anthrax provides technical basis.
尽管,现有技术中也存在山茶炭疽菌遗传转化体系的相关研究,但是其多采用裂解酶对山茶炭疽菌的原生质体进行提取所获得的原生质体数量少,质量差,且步骤繁琐,导致山茶炭疽菌的遗传转化效率不高。Although there are related studies on the genetic transformation system of Camellia anthracnose in the prior art, most of them use lyase to extract the protoplasts of Camellia anthracnose, and the protoplasts obtained are small in number, poor in quality, and the steps are cumbersome. The genetic transformation efficiency of anthrax bacteria is not high.
发明内容Contents of the invention
本发明的目的在于提供一种炭疽菌原生质体的制备方法及遗传转化体系的构建方法,所述炭疽菌原生质体的制备方法制备得到的原生质体数量多,质量好且步骤简便,进而可以提高后续遗传转化体系的转化效率。The object of the present invention is to provide a kind of preparation method of anthrax bacteria protoplast and the construction method of genetic transformation system, the number of protoplasts prepared by the preparation method of described anthrax bacteria protoplast is large, the quality is good and the steps are simple and convenient, and then can improve follow-up Transformation efficiency of genetic transformation systems.
本发明提供了一种炭疽菌原生质体的制备方法,包括如下步骤:The invention provides a kind of preparation method of protoplast of anthrax bacterium, comprises the steps:
将炭疽菌菌丝与酶解液混合,裂解,得到裂解液;mixing mycelia of the anthracnose bacteria with the enzymatic solution, and cracking to obtain the lysate;
将所述裂解液培养3~8h,得到原生质体液,所述原生质体液中包括炭疽菌原生质体;Cultivating the lysate for 3-8 hours to obtain a protoplast body fluid, which includes Bacillus anthracis protoplasts;
所述酶解液包括溶剂和溶质,所述溶剂包括磷酸缓冲液,所述溶质包括崩溃酶1~3wt.%和溶壁酶0.5~1wt.%。The enzymolysis solution includes a solvent and a solute, the solvent includes a phosphate buffer, and the solute includes 1-3 wt.% of a collapse enzyme and 0.5-1 wt.% of a lysozyme.
优选的,所述炭疽菌原生质体在所述原生质体液中的浓度为(1.6~3.6)×107个/mL。Preferably, the concentration of the anthrax protoplasts in the protoplast fluid is (1.6-3.6)×10 7 cells/mL.
优选的,所述裂解的震荡频率为80~120rpm,温度为28~32℃,时间为10~30min。Preferably, the oscillating frequency of the cracking is 80-120 rpm, the temperature is 28-32° C., and the time is 10-30 min.
优选的,所述炭疽菌包括山茶炭疽菌。Preferably, the anthracnose bacteria include Bacillus anthracis camellia.
优选的,所述炭疽菌菌丝的制备方法包括:Preferably, the preparation method of the mycelium of the anthrax mycelium comprises:
将活化的炭疽菌菌株接种至孢子培养基中进行孢子培养,得到分生孢子;Inoculating the activated anthrax bacterial strain into a spore medium for spore culture to obtain conidia;
将所述分生孢子接种至菌丝培养基中进行菌丝培养,得到炭疽菌菌丝;所述菌丝培养的震荡频率为150~200rpm,温度为25~28℃,时间为12~16h。The conidia are inoculated into mycelium medium for mycelial culture to obtain anthrax mycelium; the vibration frequency of the mycelium culture is 150-200 rpm, the temperature is 25-28° C., and the time is 12-16 hours.
本发明还提供了上述技术方案所述的制备方法在构建炭疽菌遗传转化体系中的应用。The present invention also provides the application of the preparation method described in the above technical scheme in constructing the genetic transformation system of Bacillus anthracis.
本发明还提供了一种炭疽菌遗传转化体系的构建方法,包括如下步骤:The present invention also provides a method for constructing an anthrax genetic transformation system, comprising the following steps:
采用上述技术方案所述的制备方法制备得到炭疽菌原生质体;The preparation method described in the above technical scheme is used to prepare the anthrax protoplast;
将所述炭疽菌原生质体与STC溶液混合,得到炭疽菌原生质体悬浮液;The anthrax protoplasts are mixed with the STC solution to obtain an anthrax protoplast suspension;
将所述炭疽菌原生质体悬浮液、含有抗生素标记基因和目的基因的质粒、肝素钠溶液混合,0~4℃静置30min,得到第一原生质体溶液;Mix the protoplast suspension of the anthrax bacteria, the plasmid containing the antibiotic marker gene and the target gene, and the sodium heparin solution, and let stand at 0-4°C for 30 minutes to obtain the first protoplast solution;
向所述第一原生质体溶液中逐滴加入SPTC溶液,0~4℃静置30min,得到第二原生质体溶液;Add SPTC solution dropwise to the first protoplast solution, and let stand at 0-4°C for 30 minutes to obtain a second protoplast solution;
将所述第二原生质体溶液悬浮于再生培养基复苏,得到复苏的原生质体溶液;Suspending the second protoplast solution in the regeneration medium for recovery to obtain a recovered protoplast solution;
将所述复苏的原生质体溶液与选择性培养基混合,暗培养3~5d,得到炭疽菌遗传转化体系。The resuscitated protoplast solution is mixed with a selective medium, and cultured in the dark for 3-5 days to obtain an anthracis genetic transformation system.
优选的,所述炭疽菌原生质体悬浮液的体积、含有抗生素标记基因和目的基因的质粒的质量和肝素钠溶液的体积的比值为0~100μL:1~5μg:1~2μL;所述炭疽菌原生质体悬浮液中山茶炭疽菌原生质体的浓度为(1~3)×105个/μL;所述肝素钠溶液的浓度为0.1g/mL。Preferably, the ratio of the volume of the protoplast suspension of the anthrax bacteria, the mass of the plasmid containing the antibiotic marker gene and the target gene, and the volume of the sodium heparin solution is 0-100 μL: 1-5 μg: 1-2 μL; The concentration of the protoplasts of Camellia anthracis in the protoplast suspension is (1-3)×10 5 /μL; the concentration of the sodium heparin solution is 0.1 g/mL.
优选的,所述再生培养基以水为溶剂,包括:酵母粉1wt.%,酪蛋氨基酸1wt.%和蔗糖274wt.%;pH值为7.0;Preferably, the regeneration medium uses water as a solvent, including: 1 wt.% of yeast powder, 1 wt.% of casamino acids and 274 wt.% of sucrose; the pH value is 7.0;
所述选择性培养基以水为溶剂,包括:马铃薯汁20wt.%,葡萄糖2wt.%,琼脂1.5wt.%和与所述抗生素标记基因对应的抗生素。The selective medium uses water as a solvent and includes: 20wt.% of potato juice, 2wt.% of glucose, 1.5wt.% of agar and antibiotics corresponding to the antibiotic marker gene.
优选的,所述抗生素标记基因包括G418抗性表达基因。Preferably, the antibiotic marker gene includes G418 resistance expression gene.
有益效果:Beneficial effect:
本发明提供了一种炭疽菌原生质体的制备方法,包括如下步骤:将炭疽菌菌丝与酶解液混合,震荡裂解,得到裂解液;将所述裂解液进行震荡培养3~8h,得到原生质体液,所述原生质体液中包括炭疽菌原生质体;所述酶解液以磷酸缓冲液为溶剂,包括崩溃酶1~3wt.%和溶壁酶0.5~1wt.%。本发明以磷酸缓冲液溶解崩溃酶和溶壁酶制备成的酶解液对炭疽菌菌丝进行裂解制备炭疽菌原生质体,获得的原生质体数量多,质量好,且步骤简便易操作。以此方法获得的炭疽菌原生质体可以快速有效获得PEG介导的炭疽菌遗传转化体系,且转化效率较高。The invention provides a method for preparing protoplasts of Bacillus anthracis, comprising the following steps: mixing mycelia of Bacillus anthracis with an enzymatic hydrolysis solution, shaking and lyzing to obtain a lysate; performing shaking culture on the lysate for 3 to 8 hours to obtain protoplasts Body fluid, the protoplast body fluid includes anthrax protoplasts; the enzymolysis solution uses phosphate buffer as a solvent and includes 1-3 wt.% of collapsing enzyme and 0.5-1 wt.% of lysozyme. The invention uses the enzymolysis solution prepared by dissolving the collapse enzyme and the lysozyme in the phosphate buffer solution to crack the mycelia of the anthrax bacteria to prepare the anthracis bacteria protoplasts, and the obtained protoplasts are large in quantity and good in quality, and the steps are simple and easy to operate. The anthracis protoplasts obtained in this way can quickly and effectively obtain a PEG-mediated anthrax genetic transformation system, and the transformation efficiency is high.
附图说明Description of drawings
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍。In order to illustrate the embodiments of the present invention or the technical solutions in the prior art more clearly, the following will briefly introduce the drawings required in the embodiments.
图1为实施例1~6和对比例1中制备得到的裂解液中的炭疽菌原生质体数量统计图;Fig. 1 is the statistical figure of the anthrax protoplast quantity in the lysate prepared in the
图2为实施例1~6和对比例1中制备得到的裂解液中的炭疽菌原生质体形态图;Fig. 2 is the anthrax protoplast morphological figure in the lysate prepared in the
图3为实施例7中的G418抗性筛选结果;Fig. 3 is the G418 resistance screening result in embodiment 7;
图4为测试例2中转化子基因组提取的琼脂糖凝胶电泳检测图;Fig. 4 is the agarose gel electrophoresis detection figure that transformant genome extracts in test example 2;
图5为测试例2中转化子中目的基因PCR扩增的琼脂糖凝胶电泳检测图;Fig. 5 is the agarose gel electrophoresis detection picture of target gene PCR amplification in the transformant in test example 2;
图6为测试例2中荧光显微镜下观察转化子中的GFP荧光图;Fig. 6 is the GFP fluorescence picture observed in the transformant under a fluorescence microscope in Test Example 2;
图7为实施例8中山茶炭疽菌遗传转化体系的构建方法的流程图。Fig. 7 is a flow chart of the method for constructing the genetic transformation system of Camellia anthracis in Example 8.
具体实施方式Detailed ways
本发明提供了一种炭疽菌原生质体的制备方法,包括如下步骤:The invention provides a kind of preparation method of protoplast of anthrax bacterium, comprises the steps:
将炭疽菌菌丝与酶解液混合,裂解,得到裂解液;mixing mycelia of the anthracnose bacteria with the enzymatic solution, and cracking to obtain the lysate;
将所述裂解液培养3~8h,得到原生质体液,所述原生质体液中包括炭疽菌原生质体;Cultivating the lysate for 3-8 hours to obtain a protoplast body fluid, which includes Bacillus anthracis protoplasts;
所述酶解液包括溶剂和溶质,所述溶剂包括磷酸缓冲液,所述溶质包括崩溃酶1~3wt.%和溶壁酶0.5~1wt.%。The enzymolysis solution includes a solvent and a solute, the solvent includes a phosphate buffer, and the solute includes 1-3 wt.% of a collapse enzyme and 0.5-1 wt.% of a lysozyme.
在本发明中,所述炭疽菌优选包括植物炭疽菌,进一步优选包括山茶炭疽菌。本发明对所述山茶炭疽菌的菌株没有特殊限定,本领域中常规山茶炭疽菌菌株均可以采用本发明中的制备方法制备原生质体,如本发明实施例中采用的是山茶炭疽菌LS_19菌株。In the present invention, the anthracnose bacteria preferably include Bacillus anthracis plantarum, more preferably Bacillus anthracis camellia. The present invention has no special limitation on the strain of the camellia anthracnose, and the conventional camellia anthracnose strains in the art can adopt the preparation method in the present invention to prepare protoplasts, such as the camellia anthracnose LS_19 strain used in the embodiment of the present invention.
本发明优选制备炭疽菌菌丝,所述炭疽菌菌丝的制备方法优选包括:The present invention preferably prepares anthrax mycelia, and the preparation method of said anthrax mycelia preferably includes:
将活化的炭疽菌菌株接种至孢子培养基中进行孢子培养,得到分生孢子;Inoculating the activated anthrax bacterial strain into a spore medium for spore culture to obtain conidia;
将所述分生孢子接种至菌丝培养基中进行菌丝培养,得到炭疽菌菌丝;所述菌丝培养的震荡频率为150~200rpm,温度为25~28℃,时间为12~16h。The conidia are inoculated into mycelium medium for mycelial culture to obtain anthrax mycelium; the vibration frequency of the mycelium culture is 150-200 rpm, the temperature is 25-28° C., and the time is 12-16 hours.
本发明优选将活化的炭疽菌菌株接种至孢子培养基中进行孢子培养,得到孢子培养液。本发明所述炭疽菌菌株的接种量与孢子培养基的体积比优选为(1~5):(10~50),更优选为1:50。本发明对所述炭疽菌菌株的活化方法没有特殊限定,采用本领域中常规活化方法即可。本发明所述孢子培养基优选包括PDB液体培养基。本发明所述孢子培养优选为恒温震荡培养,所述孢子培养优选于摇床上进行。本发明所述孢子培养的震荡频率优选为150~200rpm,更优选为200rpm;温度优选为25~28℃,更优选为28℃;时间优选为60~72h,更优选为72h。本发明所述孢子培养优选为黑暗培养。In the present invention, preferably, the activated anthracis bacterial strain is inoculated into a spore culture medium for spore culture to obtain a spore culture solution. The volume ratio of the inoculum amount of the anthracis strain of the present invention to the spore culture medium is preferably (1-5):(10-50), more preferably 1:50. In the present invention, there is no special limitation on the activation method of the anthrax strain, and conventional activation methods in the art can be used. The spore culture medium of the present invention preferably comprises PDB liquid culture medium. The spore culture of the present invention is preferably a constant temperature shaking culture, and the spore culture is preferably carried out on a shaker. The shaking frequency of the spore culture in the present invention is preferably 150-200 rpm, more preferably 200 rpm; the temperature is preferably 25-28°C, more preferably 28°C; the time is preferably 60-72h, more preferably 72h. The spore culture of the present invention is preferably dark culture.
得到所述孢子培养液后,本发明优选还包括将所述孢子培养液进行过滤,将得到的培养液进行第一离心,弃上清,得到分生孢子。本发明优选采用覆盖有过滤膜的灭菌漏斗进行所述过滤。所述过滤膜优选包括三层Miracloth过滤膜,所述Miracloth过滤膜的孔径优选为22~25mm,更优选为22mm;所述Miracloth过滤膜的材质优选为聚酯人造纤维滤布。本发明进行所述过滤前优选还包括对所述过滤膜进行高压灭菌和烘干,所述高压灭菌的温度优选为121℃,时间为20min。本发明所述第一离心的温度优选为0~4℃,更优选为4℃,转速优选为3000~5000rpm,更优选为5000rpm,时间优选为3~10min,更优选为5min。After obtaining the spore culture solution, the present invention preferably further includes filtering the spore culture solution, performing first centrifugation on the obtained culture solution, and discarding the supernatant to obtain conidia. The present invention preferably uses a sterilized funnel covered with a filter membrane to carry out the filtration. The filter membrane preferably includes three layers of Miracloth filter membranes, and the pore size of the Miracloth filter membrane is preferably 22-25mm, more preferably 22mm; the material of the Miracloth filter membrane is preferably polyester rayon filter cloth. The present invention preferably further includes autoclaving and drying the filter membrane before performing the filtration, and the temperature of the autoclaving is preferably 121° C. for 20 minutes. The temperature of the first centrifugation in the present invention is preferably 0-4°C, more preferably 4°C, the rotation speed is preferably 3000-5000rpm, more preferably 5000rpm, and the time is preferably 3-10min, more preferably 5min.
得到所述分生孢子后,本发明优选将所述分生孢子接种至菌丝培养基中进行菌丝培养,得到炭疽菌菌丝培养液。本发明所述菌丝培养基优选包括M3S液体培养基。本发明所述菌丝培养的震荡频率优选为150~200rpm,更优选为200rpm;温度优选为25~28℃,更优选为28℃;时间优选为12~16h,更优选为14h。本发明所述12~16h的震荡培养可以使炭疽菌菌丝保持适宜的成熟度,避免因菌丝过于成熟而降低裂解得到的原生质体的数量和质量。本发明所述菌丝培养优选为恒温培养。After the conidia are obtained, the present invention preferably inoculates the conidia into a mycelial culture medium for mycelial culture to obtain a mycelial culture solution for Mycelium anthracis. The mycelia culture medium of the present invention preferably includes M3S liquid culture medium. The vibration frequency of mycelia culture in the present invention is preferably 150-200 rpm, more preferably 200 rpm; the temperature is preferably 25-28°C, more preferably 28°C; the time is preferably 12-16h, more preferably 14h. The shaking culture for 12-16 hours in the present invention can keep the mycelia of the anthracnose fungus at a suitable maturity, and avoid reducing the quantity and quality of protoplasts obtained by cracking due to over-mature mycelia. The mycelia culture in the present invention is preferably constant temperature culture.
得到所述炭疽菌菌丝培养液后,本发明优选将所述炭疽菌菌丝培养液进行过滤。本发明进行所述过滤使用的过滤装置优选与上述进行孢子培养液过滤时使用的过滤装置相同,不再赘述。After obtaining the mycelia culture solution of the anthracis bacteria, the present invention preferably filters the culture solution of the bacteria mycelium anthracis. The filter device used for the filtration in the present invention is preferably the same as the filter device used for the above-mentioned filtration of the spore culture solution, and will not be repeated here.
所述过滤后,本发明优选使用无菌水对过滤得到的菌丝进行冲洗,得到炭疽菌菌丝。本发明所述冲洗的次数优选为3次。After the filtration, the present invention preferably uses sterile water to rinse the filtered mycelia to obtain the anthracis mycelia. The number of flushing in the present invention is preferably 3 times.
得到所述炭疽菌菌丝后,本发明将所述炭疽菌菌丝与酶解液混合,裂解,得到裂解液。本发明所述炭疽菌菌丝与酶解液的质量体积比优选为0.1~1g:5~20mL,更优选为0.1~1g:10mL。本发明所述酶解液优选包括溶剂和溶质,所述溶剂优选包括磷酸缓冲液,所述溶质优选包括崩溃酶1~3wt.%和溶壁酶0.5~1wt.%,更优选包括崩溃酶2wt.%和溶壁酶1wt.%。与常规裂解酶相比,本发明所述酶解液裂解效果更好,裂解获得的原生质数量更多,质量更好。本发明所述裂解的震荡频率优选为80~120rpm,更优选为100rpm;温度优选为28~32℃,更优选为30.5℃;时间优选为10~30min,更优选为20min。本发明所述裂解优选于摇床上进行。After the mycelia of the anthracis fungus are obtained, the present invention mixes the mycelia of the anthracis fungus with an enzymatic hydrolysis solution, and cracks to obtain a lysate. The mass-to-volume ratio of the mycelium of the anthracnose fungi and the enzymatic hydrolysis solution in the present invention is preferably 0.1-1 g: 5-20 mL, more preferably 0.1-1 g: 10 mL. The enzymolysis solution of the present invention preferably includes a solvent and a solute, the solvent preferably includes a phosphate buffer, the solute preferably includes 1 to 3 wt.% of a collapsing enzyme and 0.5 to 1 wt.% of a lytic enzyme, and more preferably includes 2 wt of a collapsing enzyme .% and lysozyme 1wt.%. Compared with conventional lyases, the enzymatic hydrolysis solution of the present invention has a better lysis effect, and the protoplasts obtained by lysis are more in quantity and better in quality. The oscillation frequency of the cracking in the present invention is preferably 80-120 rpm, more preferably 100 rpm; the temperature is preferably 28-32°C, more preferably 30.5°C; the time is preferably 10-30min, more preferably 20min. The lysis in the present invention is preferably carried out on a shaker.
得到所述裂解液后,本发明优选还包括对所述裂解液进行过滤。本发明优选采用细菌过滤器进行所述过滤,所述细菌过滤器的孔径优选为0.22μm。After obtaining the lysate, the present invention preferably further includes filtering the lysate. In the present invention, a bacterial filter is preferably used for the filtration, and the pore size of the bacterial filter is preferably 0.22 μm.
所述过滤后,本发明优选将得到的裂解液培养2~8h,得到原生质体液。本发明所述培养的震荡频率优选为80~120rpm,更优选为100rpm;温度优选为28~30℃,更优选为30.5℃。本发明所述培养的时间优选为5~8h,进一步优选为6~7h,更优选为7h。本发明所述原生质体液中包括炭疽菌原生质体,所述炭疽菌原生质体在所述原生质体液中的浓度优选为(1.6~3.6)×107个/mL,更优选为3.6×107个/mL。本发明在所述培养2h后,优选还包括每1小时对所述培养的原生质体液观察一次,直至达到上述浓度。本发明所述培养优选在摇床上进行。After the filtration, the present invention preferably cultures the obtained lysate for 2-8 hours to obtain the protoplast body fluid. The shaking frequency of the culture in the present invention is preferably 80-120 rpm, more preferably 100 rpm; the temperature is preferably 28-30°C, more preferably 30.5°C. The time for culturing in the present invention is preferably 5-8 hours, more preferably 6-7 hours, more preferably 7 hours. The protoplast body fluid of the present invention includes Bacillus anthracis protoplasts, and the concentration of the Bacillus anthracis protoplasts in the protoplast body fluid is preferably (1.6-3.6)×10 7 /mL, more preferably 3.6×10 7 /mL mL. After 2 hours of the culture, the present invention preferably further includes observing the body fluid of the cultured protoplast every 1 hour until the above concentration is reached. The cultivation in the present invention is preferably carried out on a shaker.
得到所述原生质体溶液后,本发明优选对所述原生质体液进行第二离心,弃上清,得到炭疽菌原生质体。本发明所述第二离心的温度优选为0~4℃,更优选为4℃,转速优选为2000~4000rpm,更优选为3000rpm,时间优选为3~10min,更优选为5min。After the protoplast solution is obtained, the present invention preferably performs second centrifugation on the protoplast body liquid, discards the supernatant, and obtains the anthrax protoplast. The temperature of the second centrifugation in the present invention is preferably 0-4°C, more preferably 4°C, the rotation speed is preferably 2000-4000rpm, more preferably 3000rpm, and the time is preferably 3-10min, more preferably 5min.
本发明以磷酸缓冲液溶解崩溃酶和溶壁酶制备成酶解液对炭疽菌菌丝进行裂解制备炭疽菌原生质体,获得的原生质体数量多,质量好,且步骤简便易操作。The invention prepares an enzymolysis solution by dissolving the collapse enzyme and the wall-lyzing enzyme in a phosphate buffer solution to crack the mycelia of the anthracis fungus to prepare the protoplast of the anthracis fungus, and the protoplasts obtained are large in quantity and good in quality, and the steps are simple and easy to operate.
基于上述优势,本发明还提供了上述技术方案所述的制备方法在构建炭疽菌遗传转化体系中的应用。本发明所述炭疽菌优选包括植物炭疽菌,更优选包括山茶炭疽菌。Based on the above-mentioned advantages, the present invention also provides the application of the preparation method described in the above-mentioned technical solution in constructing an anthracis genetic transformation system. The anthracnose bacteria described in the present invention preferably include plant anthracnose, more preferably include anthracnose camellia.
本发明还提供了一种炭疽菌遗传转化体系的构建方法,包括如下步骤:The present invention also provides a method for constructing an anthrax genetic transformation system, comprising the following steps:
采用上述技术方案所述的制备方法制备得到炭疽菌原生质体;The preparation method described in the above technical scheme is used to prepare the anthrax protoplast;
将所述炭疽菌原生质体与STC溶液混合,得到炭疽菌原生质体悬浮液;The anthrax protoplasts are mixed with the STC solution to obtain an anthrax protoplast suspension;
将所述炭疽菌原生质体悬浮液、含有抗生素标记基因和目的基因的质粒、肝素钠溶液混合,0~4℃静置30min,得到第一原生质体溶液;Mix the protoplast suspension of the anthrax bacteria, the plasmid containing the antibiotic marker gene and the target gene, and the sodium heparin solution, and let stand at 0-4°C for 30 minutes to obtain the first protoplast solution;
向所述第一原生质体溶液中加入SPTC溶液,0~4℃静置30min,得到第二原生质体溶液;adding SPTC solution to the first protoplast solution, and standing at 0-4°C for 30 minutes to obtain a second protoplast solution;
将所述第二原生质体溶液悬浮于再生培养基中复苏,得到复苏的原生质体溶液;Suspending the second protoplast solution in regeneration medium for recovery to obtain a recovered protoplast solution;
将所述复苏的原生质体溶液与选择性培养基混合,暗培养3~5d,得到炭疽菌遗传转化体系。The resuscitated protoplast solution is mixed with a selective medium, and cultured in the dark for 3-5 days to obtain an anthracis genetic transformation system.
在本发明中,所述炭疽菌遗传转化体系优选包括炭疽菌遗传转化体系。In the present invention, the anthracis genetic transformation system preferably includes an anthracis genetic transformation system.
本发明采用上述技术方案所述的制备方法制备炭疽菌原生质体。本发明制备所述炭疽菌原生质体的步骤和过程优选与上述技术方案相同,不再进行赘述。The present invention adopts the preparation method described in the above technical scheme to prepare the anthracis protoplast. The steps and process for preparing the protoplasts of B. anthracis in the present invention are preferably the same as the above-mentioned technical solution, and will not be repeated here.
得到所述炭疽菌原生质体后,本发明将所述炭疽菌原生质体与STC溶液混合,得到炭疽菌原生质体悬浮液。本发明所述混合过程优选包括:将炭疽菌原生质体与STC溶液混合和第三离心,重复此过程两次。本发明所述第三离心的条件优选与所述第二离心的条件相同,不再赘述。本发明所述炭疽菌原生质体悬浮液中炭疽菌原生质体的浓度优选为(1~3)×105个/μL。After the anthrax protoplasts are obtained, the present invention mixes the anthrax protoplasts with an STC solution to obtain an anthrax protoplast suspension. The mixing process of the present invention preferably includes: mixing the anthracis protoplasts with the STC solution and centrifuging for the third time, and repeating this process twice. The conditions of the third centrifugation in the present invention are preferably the same as the conditions of the second centrifugation, and will not be repeated here. The concentration of the anthracis protoplasts in the anthracis protoplast suspension in the present invention is preferably (1-3)×10 5 /μL.
得到所述炭疽菌原生质体悬浮液后,本发明将所述炭疽菌原生质体悬浮液、含有抗生素标记基因和目的基因的质粒、肝素钠溶液混合,0~4℃静置30min,得到第一原生质体溶液。本发明所述炭疽菌原生质体悬浮液的体积、含有抗生素标记基因和目的基因的质粒的质量和肝素钠溶液的体积的比值为优选为20~100μL:1~5μg:1~2μL,更优选为50μL:2μg:1μL。本发明所述肝素钠溶液的浓度优选为0.1g/mL。本发明所述含有抗生素标记基因和目的基因的质粒中的抗性标记基因优选包括G418抗性表达基因或潮霉素B抗性表达基因,更优选为G418抗性表达基因。本发明所述含有抗生素标记基因和目的基因的质粒中初始质粒优选包括pBlueScriptⅡ(+)、pBARGPE1-Hygro(+)或pBin(+)质粒,更优选为pBlueScriptⅡ(+)质粒。本发明对所述含有抗生素标记基因和目的基因的质粒中的目的基因没有特殊限定,任意炭疽菌相关基因或模式标记基因均可,如本发明实施例中采用的是绿色荧光蛋白GFP基因。After obtaining the anthrax protoplast suspension, the present invention mixes the anthrax protoplast suspension, a plasmid containing an antibiotic marker gene and a target gene, and a sodium heparin solution, and leaves it standing at 0-4°C for 30 minutes to obtain the first protoplast body solution. The ratio of the volume of the anthrax protoplast suspension of the present invention, the quality of the plasmid containing the antibiotic marker gene and the target gene, and the volume of the sodium heparin solution is preferably 20-100 μL: 1-5 μg: 1-2 μL, more preferably 50 μL: 2 μg: 1 μL. The concentration of the heparin sodium solution in the present invention is preferably 0.1 g/mL. The resistance marker gene in the plasmid containing the antibiotic marker gene and the target gene of the present invention preferably includes a G418 resistance expression gene or a hygromycin B resistance expression gene, more preferably a G418 resistance expression gene. Among the plasmids containing antibiotic marker genes and target genes in the present invention, the initial plasmids preferably include pBlueScriptII(+), pBARGPE1-Hygro(+) or pBin(+) plasmids, more preferably pBlueScriptII(+) plasmids. The present invention has no special limitation on the target gene in the plasmid containing the antibiotic marker gene and the target gene, any anthrax-related gene or model marker gene is acceptable, such as the green fluorescent protein GFP gene used in the embodiment of the present invention.
得到所述第一原生质体溶液后,本发明向所述第一原生质体溶液中加入SPTC溶液,0~4℃静置30min,得到第二原生质体溶液。本发明所述SPTC溶液与所述炭疽菌原生质体悬浮液的体积比优选为2:1。本发明所述加入优选为逐滴加入,采用逐滴加入的方式将所述SPTC溶液加入所述第一原生质体溶液中的方式通过引起细胞膜表面电荷的紊乱,干扰细胞间的识别,从而有利于细胞间融合和外源DNA分子进入原生质体。After obtaining the first protoplast solution, the present invention adds SPTC solution to the first protoplast solution, and leaves it standing at 0-4° C. for 30 minutes to obtain the second protoplast solution. The volume ratio of the SPTC solution in the present invention to the anthracis protoplast suspension is preferably 2:1. The addition of the present invention is preferably dropwise addition, and the method of adding the SPTC solution to the first protoplast solution by adding dropwise will interfere with the recognition between cells by causing the disorder of the surface charge of the cell membrane, thereby facilitating Cell-to-cell fusion and entry of foreign DNA molecules into protoplasts.
得到所述第二原生质体溶液后,本发明将所述第二原生质体溶液悬浮于再生培养基中复苏,得到复苏的原生质体溶液。本发明所述第二原生质体溶液与所述再生培养基的体积比优选为1:20。本发明所述再生培养基优选以水为溶剂,还包括:酵母粉1wt.%,酪蛋氨基酸1wt.%和蔗糖274wt.%;所述再生培养基的pH值优选为7.0。本发明优选于恒温震荡培养箱中进行所述复苏,所述复苏的温度优选为25~28℃,更优选为26℃;震荡频率优选为80~120rpm,更优选为100rpm;时间优选为12~16h,更优选为16h。After the second protoplast solution is obtained, the present invention suspends the second protoplast solution in regeneration medium for recovery to obtain a recovered protoplast solution. The volume ratio of the second protoplast solution in the present invention to the regeneration medium is preferably 1:20. The regeneration medium of the present invention preferably uses water as a solvent, and further includes: 1 wt.% of yeast powder, 1 wt.% of casamino acids and 274 wt.% of sucrose; the pH value of the regeneration medium is preferably 7.0. In the present invention, the resuscitation is preferably carried out in a constant temperature shaking incubator, the temperature of the resuscitation is preferably 25-28°C, more preferably 26°C; the shaking frequency is preferably 80-120rpm, more preferably 100rpm; the time is preferably 12-28°C. 16h, more preferably 16h.
得到所述复苏的原生质体溶液后,本发明将所述复苏的原生质体溶液与选择性培养基混合,暗培养3~5d,得到炭疽菌遗传转化体系。本发明所述复苏的原生质体溶液与选择培养基的体积比优选为1~3:10~30,更优选为1:20。本发明进行所述暗培养前,优选还包括将所述复苏的原生质体溶液与选择性培养基的混合物倒入培养皿中。本发明所述暗培养优选在恒温培养箱中进行。本发明所述暗培养的时间优选为5d;温度优选为25~28℃,更优选为28℃。本发明所述选择性培养基优选以水为溶剂,包括:马铃薯汁20wt.%,葡萄糖2wt.%,琼脂1.5wt.%和与所述抗生素标记基因对应的抗生素;所述选择性培养基的pH值优选为自然值。本发明所述抗生素的浓度优选依据所述抗生素标记基因进行设定;在本发明的实施例中,选择培养基中包括G418(遗传霉素),且所述G418的浓度优选为150μg/mL。After obtaining the revived protoplast solution, the present invention mixes the revived protoplast solution with a selective medium and cultures in dark for 3-5 days to obtain an anthrax genetic transformation system. The volume ratio of the recovered protoplast solution to the selection medium in the present invention is preferably 1-3:10-30, more preferably 1:20. The present invention preferably further includes pouring the mixture of the resuscitated protoplast solution and the selective medium into a petri dish before performing the dark culture. The dark culture of the present invention is preferably carried out in a constant temperature incubator. The time of the dark cultivation in the present invention is preferably 5 days; the temperature is preferably 25-28°C, more preferably 28°C. The selective medium of the present invention preferably uses water as a solvent, including: 20wt.% of potato juice, 2wt.% of glucose, 1.5wt.% of agar and antibiotics corresponding to the antibiotic marker gene; The pH value is preferably a natural value. The concentration of the antibiotic in the present invention is preferably set according to the antibiotic marker gene; in an embodiment of the present invention, G418 (geneticin) is included in the selection medium, and the concentration of G418 is preferably 150 μg/mL.
为了进一步说明本发明,下面结合附图和实施例对本发明提供的技术方案进行详细地描述,但不能将它们理解为对本发明保护范围的限定。In order to further illustrate the present invention, the technical solutions provided by the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the protection scope of the present invention.
下述实施例中使用的试剂、培养基及配制方法:Reagents, medium and preparation methods used in the following examples:
PDA固体培养基:以水为溶剂,马铃薯汁20wt.%,葡萄糖2wt.%,琼脂2wt.%,pH值为自然值,121℃高压灭菌20min;PDA solid medium: use water as solvent, potato juice 20wt.%, glucose 2wt.%, agar 2wt.%, pH value is natural value, autoclaved at 121°C for 20min;
PDB液体培养基:以水为溶剂,马铃薯汁20wt.%,葡萄糖2wt.%,pH值为自然值,121℃高压灭菌20min;PDB liquid medium: use water as solvent, potato juice 20wt.%, glucose 2wt.%, pH value is natural value, autoclave at 121°C for 20min;
M3S液体培养基:以水为溶剂,七水合硫酸镁2.5wt.%,磷酸二氢钾2.7wt.%,蛋白胨1wt.%,酵母膏1wt.%,蔗糖10wt.%,pH自然值,121℃高压灭菌20min;M3S liquid medium: use water as solvent, magnesium sulfate heptahydrate 2.5wt.%, potassium dihydrogen phosphate 2.7wt.%, peptone 1wt.%, yeast extract 1wt.%, sucrose 10wt.%, pH natural value, 121°C Autoclave for 20 minutes;
再生培养基:以水为溶剂,酵母粉1wt.%,酪蛋氨基酸1wt.%,蔗糖274wt.%,pH值为7.0,121℃高压灭菌20min;Regeneration medium: use water as solvent, yeast powder 1wt.%, casein amino acid 1wt.%, sucrose 274wt.%, pH value 7.0, autoclave at 121°C for 20 minutes;
菌株选择性培养基:以水为溶剂,马铃薯汁20wt.%,葡萄糖2wt.%,琼脂1.5wt.%,pH自然值,121℃高压灭菌20min,按照所要获得培养基中的G418浓度,加入相对应浓度的G418;Strain selective medium: use water as solvent, potato juice 20wt.%, glucose 2wt.%, agar 1.5wt.%, pH natural value, autoclave at 121°C for 20min, according to the concentration of G418 in the medium to be obtained, add Corresponding concentration of G418;
LB液体培养基:以水为溶剂,酵母粉5wt.%,氯化钠10wt.%,胰蛋白胨10wt.%,pH=7.0,121℃高压灭菌20min;LB liquid medium: use water as solvent, yeast powder 5wt.%, sodium chloride 10wt.%, tryptone 10wt.%, pH=7.0, autoclave at 121°C for 20 minutes;
肝素钠溶液:100mg肝素钠粉末溶于1mL无菌蒸馏水中,0.22μm细菌过滤器进行过滤除菌;Heparin sodium solution: 100mg of heparin sodium powder was dissolved in 1mL sterile distilled water, and sterilized by filtration with a 0.22μm bacterial filter;
G418:购买于北京酷来搏科技有限公司;G418: purchased from Beijing Kulaibo Technology Co., Ltd.;
酶解液:崩溃酶2wt.%,溶壁酶1wt.%,10mL磷酸缓冲液,0.22μm细菌过滤器进行过滤除菌,其中磷酸缓冲液为:以水为溶剂,氯化钠7wt.%,氯化钙1wt.%,磷酸氢二钠0.5wt.%,pH自然值,使用双蒸水定容到1L,121℃灭菌20min;Enzymolysis solution: 2wt.% of collapsing enzyme, 1wt.% of lysozyme, 10mL phosphate buffer, 0.22μm bacterial filter for filter sterilization, wherein the phosphate buffer is: water as solvent, sodium chloride 7wt.%, Calcium chloride 1wt.%, disodium hydrogen phosphate 0.5wt.%, pH natural value, use double distilled water to make up to 1L, sterilize at 121°C for 20min;
STC试剂:Sorbitol 145.6g,Tris 6.05g,CaCl2·H2O 7.35g,溶于1L无菌蒸馏水,pH值为7,121℃高压灭菌20min;STC reagents: Sorbitol 145.6g, Tris 6.05g, CaCl 2 ·H 2 O 7.35g, dissolved in 1L sterile distilled water, pH value is 7, autoclaved at 121°C for 20min;
SPTC试剂:40g PEG溶于100mL STC试剂,121℃高压灭菌20min。SPTC reagent: 40g PEG was dissolved in 100mL STC reagent, and autoclaved at 121°C for 20min.
实施例1Example 1
一种山茶炭疽菌原生质体的制备方法,步骤如下:A preparation method of camellia anthracnose protoplast, the steps are as follows:
A1)将新鲜的活化的山茶炭疽菌LS_19接种到PDB液体培养基中,28℃恒温摇床200rpm,黑暗培养72h,产生大量分生孢子;A1) Inoculate fresh activated Camellia anthracis LS_19 into PDB liquid medium, 28 ℃ constant temperature shaker 200rpm, dark culture 72h, produce a large number of conidia;
A2)在灭菌漏斗上覆盖三层Miracloth过滤膜,过滤上述培养液,4℃5000rpm离心5min,弃上清,收集分生孢子;A2) Cover three layers of Miracloth filter membranes on the sterilizing funnel, filter the above culture solution, centrifuge at 5000rpm at 4°C for 5min, discard the supernatant, and collect conidia;
A3)将分生孢子置于50mLM3S液体培养基中,28℃恒温摇床200rpm,黑暗培养14h,培养产生幼嫩的菌丝;A3) Place the conidia in 50 mL of M3S liquid medium, in a constant temperature shaker at 28° C. at 200 rpm, and culture in the dark for 14 hours to produce tender hyphae;
A4)在灭菌漏斗上覆盖三层Miracloth过滤膜,过滤上述溶液,收集滤膜上的幼嫩菌丝,然后用无菌水冲洗三次,将收集的1g幼嫩菌丝加入到无菌三角锥瓶中;A4) Cover three layers of Miracloth filter membranes on the sterilizing funnel, filter the above solution, collect the young mycelium on the filter membrane, then rinse three times with sterile water, add the 1g young mycelium of collection to the sterile triangular cone in the bottle;
A5)配制10mL酶解液(10mL磷酸缓冲液中含有崩溃酶2wt.%和溶壁酶1wt.%),30.5℃恒温摇床100rpm,摇培10~30min,0.22μm细菌过滤器进行过滤除菌后加入至三角锥瓶中;A5) Prepare 10mL enzymatic hydrolysis solution (10mL phosphate buffer contains 2wt.% collapsing enzyme and 1wt.% lysozyme), 30.5°C constant temperature shaker at 100rpm, shaking culture for 10-30min, 0.22μm bacterial filter for filter sterilization After adding to the Erlenmeyer flask;
A6)将上述溶液放置于恒温振荡培养箱中,温度为30.5℃,转速为100rpm,培养7h,两个小时后,每隔1小时观察一次,获得原生质体液;A6) Place the above solution in a constant temperature shaking incubator at a temperature of 30.5° C. and a rotation speed of 100 rpm, and incubate for 7 hours. After two hours, observe once every hour to obtain protoplast body fluid;
A7)将步骤A6)中获得的原生质体液置于离心机里,4℃3000rpm离心5min,弃上清备用。A7) Place the protoplast body fluid obtained in step A6) in a centrifuge, centrifuge at 3000 rpm at 4°C for 5 min, and discard the supernatant for later use.
实施例2Example 2
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A6)中的培养时间为8h。The preparation method in Example 1 was used to prepare protoplasts of Anthracnose camellia, with the difference that the cultivation time in step A6) was 8 hours.
实施例3Example 3
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A6)中的培养时间为6h。The preparation method in Example 1 was used to prepare protoplasts of Anthracnose camellia, with the difference that the cultivation time in step A6) was 6 h.
实施例4Example 4
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A6)中的培养时间为5h。The preparation method in Example 1 was used to prepare protoplasts of Anthracnose camellia, with the difference that the cultivation time in step A6) was 5 h.
实施例5Example 5
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A6)中的培养时间为4h。The preparation method in Example 1 was used to prepare protoplasts of Anthracnose camellia, with the difference that the cultivation time in step A6) was 4 h.
实施例6Example 6
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A6)中的培养时间为3h。The preparation method in Example 1 was used to prepare protoplasts of Anthracnose camellia, with the difference that the cultivation time in step A6) was 3 h.
对比例1Comparative example 1
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A6)中的培养时间为2h。The preparation method in Example 1 was used to prepare protoplasts of Anthracnose camellia, with the difference that the cultivation time in step A6) was 2 h.
测试例1
分别吸取适量实施例1~6和对比例1中步骤6)中制备得到的原生质体液,置于血球计数板上,在普通光学显微镜下观察原生质体数量和质量,结果如图1~2所示,其中在图2中左图和右图分别为为对比例1(2h)和实施例1(7h)中制备得到的炭疽菌原生质体的形态图;图2的标尺为100μm。Absorb appropriate amount of protoplast body fluids prepared in step 6) in Examples 1-6 and Comparative Example 1 respectively, place them on a hemocytometer, observe the quantity and quality of protoplasts under an ordinary optical microscope, and the results are shown in Figures 1-2 , where the left and right figures in Figure 2 are respectively the morphological figures of the anthrax protoplasts prepared in Comparative Example 1 (2h) and Example 1 (7h); the scale bar in Figure 2 is 100 μm.
由图1可以得出:采用实施例1~6和对比例1的制备方法制备得到的裂解溶液中的原生质体的数量分别为3.6×107、3.1×107、3.0×107、2.6×107、2.2×107、1.6×107和0.4×107个/mL;结合图2可以看出2h时可观察到具有一定数量的原生质体,但原生质体体积较小,随着裂解时间的增加,原生质体的数量不断增多,7h时,原生质体的数量最多,且原生质体圆润饱满。It can be drawn from Figure 1 that the numbers of protoplasts in the lysed solution prepared by the preparation methods of Examples 1-6 and Comparative Example 1 were 3.6×10 7 , 3.1×10 7 , 3.0×10 7 , and 2.6× 10 7 , 2.2×10 7 , 1.6×10 7 and 0.4×10 7 cells/mL; combined with Figure 2, it can be seen that a certain number of protoplasts can be observed at 2 hours, but the volume of protoplasts is small. The number of protoplasts increased continuously, and at 7 hours, the number of protoplasts was the largest, and the protoplasts were round and plump.
对比例2Comparative example 2
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A5)中的酶解液组分为10mL生理盐水中含有崩溃酶2wt.%和溶壁酶1wt.%,步骤A6)裂解的时间为2~8h。The preparation method in Example 1 is used to prepare the protoplasts of Camellia anthracis, the difference is that the enzymolysis solution component in step A5) is 10mL physiological saline containing 2wt.% of collapsing enzyme and 1wt.% of lysozyme, step A6) The cracking time is 2~8h.
将步骤A6)中制备得到的原生质体液,置于血球计数板上,在普通光学显微镜下观察原生质体数量和质量,结果发现对比例2中得到的原生质体破碎多,质量不高,裂解2~8h后获得的原生质体数量在(1~20)×105个/mL之间。The protoplast body fluid prepared in step A6) was placed on a hemocytometer, and the quantity and quality of the protoplasts were observed under an ordinary optical microscope. It was found that the protoplasts obtained in Comparative Example 2 were broken and the quality was not high. The number of protoplasts obtained after 8 hours was between (1-20)×10 5 /mL.
对比例3Comparative example 3
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A5)中的酶解液组分为10mL磷酸缓冲液中含有蜗牛酶2wt.%和溶菌酶1wt.%,步骤A6)裂解的时间为2~8h。The preparation method in Example 1 is used to prepare the protoplasts of Camellia anthracis, the difference is that the enzymolysis solution component in step A5) is 10mL phosphate buffer containing helicase 2wt.% and lysozyme 1wt.%, step A6) The cracking time is 2~8h.
将步骤A6)中制备得到的原生质体液,置于血球计数板上,在普通光学显微镜下观察原生质体数量和质量,结果发现对比例3中得到的原生质体数量少,裂解2~8h数量在(1~5)×105个/mL之间。The protoplast body fluid prepared in step A6) was placed on a hemocytometer, and the quantity and quality of the protoplasts were observed under an ordinary optical microscope. As a result, it was found that the protoplasts obtained in Comparative Example 3 were less in number, and the number of lysed 2 to 8 hours was between ( 1~5)×10 5 cells/mL.
对比例4Comparative example 4
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A5)中的酶解液组分为10mL磷酸缓冲液中含有溶壁酶2wt.%和崩溃酶1wt.%,步骤A6)裂解的时间为2~8h。The preparation method in Example 1 is used to prepare the protoplasts of Camellia anthracis, the difference is that the enzymolysis solution component in step A5) is 10mL phosphate buffer containing lysozyme 2wt.% and collapsing enzyme 1wt.%, step A6 ) cracking time is 2 ~ 8h.
将步骤A6)中制备得到的原生质体液,置于血球计数板上,在普通光学显微镜下观察原生质体数量和质量,结果发现对比例4中得到的原生质体数量少,裂解2~8h数量在(1~10)×105个/mL之间。The protoplast body fluid prepared in step A6) was placed on a hemocytometer, and the quantity and quality of the protoplasts were observed under an ordinary optical microscope. As a result, it was found that the protoplasts obtained in Comparative Example 4 were less in number, and the number of lysed 2 to 8 hours was between ( 1~10)×10 5 cells/mL.
对比例5Comparative example 5
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A5)中的酶解液组分为10mL磷酸缓冲液中含有蜗牛酶2wt.%和崩溃酶1wt.%,步骤A6)裂解的时间为2~8h。The preparation method in Example 1 was used to prepare protoplasts of Camellia anthracnose, the difference being that the enzymolysis solution component in step A5) was 10 mL of phosphate buffer containing 2 wt.% of helicase and 1 wt.% of collapsing enzyme, step A6) The cracking time is 2~8h.
将步骤A6)中制备得到的原生质体液,置于血球计数板上,在普通光学显微镜下观察原生质体数量和质量,结果发现对比例5中得到的原生质体数量少,裂解2~8h数量在(1~10)×105个/mL之间。The protoplast body fluid prepared in step A6) was placed on a hemocytometer, and the quantity and quality of protoplasts were observed under an ordinary optical microscope. It was found that the number of protoplasts obtained in Comparative Example 5 was small, and the number of lysed 2 to 8 hours was between ( 1~10)×10 5 cells/mL.
对比例6Comparative example 6
采用实施例1中的制备方法制备山茶炭疽菌原生质体,区别在于,步骤A5)中的酶解液组分为10mL磷酸缓冲液中含有蜗牛酶2wt.%,纤维素酶2wt.%和溶菌酶1wt.%,步骤A6)裂解的时间为2~8h。The preparation method in Example 1 was used to prepare protoplasts of Camellia anthracis, the difference being that the enzymolysis solution component in step A5) contained 2wt.% helicase, 2wt.% cellulase and lysozyme in 10mL phosphate buffer 1wt.%, step A6) cracking time is 2-8h.
将步骤A6)中制备得到的原生质体液,置于血球计数板上,在普通光学显微镜下观察原生质体数量和质量,结果发现对比例6中裂解2~8h基本没有原生质体。The protoplast body fluid prepared in step A6) was placed on a hemocytometer, and the quantity and quality of protoplasts were observed under an ordinary optical microscope. It was found that there were basically no protoplasts after lysis for 2-8 hours in Comparative Example 6.
实施例7Example 7
G418抗性筛选G418 Resistance Screening
山茶炭疽菌LS_19在恒温培养箱28℃黑暗培养3-5天,取5mm菌饼分别接种于含有浓度为0(CK)、50、100和150μg/mL,G418的PDA固体培养基上,置于恒温培养箱中静置培养4天,统计菌落直径并拍照记录,每个处理设置3个重复,并将该实验重复三次,结果如图3所示。Camellia anthracnose LS_19 was cultured in the dark at 28°C for 3-5 days in a constant temperature incubator, and 5mm bacterial cakes were inoculated on PDA solid medium containing G418 at a concentration of 0 (CK), 50, 100 and 150 μg/mL. The colony diameter was counted and photographed and recorded in a constant temperature incubator for 4 days. Three replicates were set for each treatment, and the experiment was repeated three times. The results are shown in Figure 3.
由图3可以看出,在150μg/mL浓度G418的PDA固体培培养基几乎不生长,而在含有浓度为0(CK)、50和100mg/mL的PDA固体培养基上均有山茶炭疽菌LS_19菌落生长,进而得到山茶炭疽菌LS_19菌株对G418的最低抑菌浓度为150μg/mL。As can be seen from Fig. 3, the PDA solid culture medium of 150 μ g/mL concentration G418 hardly grows, and on the PDA solid medium containing concentration of 0 (CK), 50 and 100 mg/mL, there is Camellia anthracis LS_19 Colony growth, and then the minimum inhibitory concentration of Camellia anthracis LS_19 strain to G418 was 150 μg/mL.
实施例8Example 8
一种山茶炭疽菌遗传转化体系的构建方法,其构建流程图如图7所示,步骤如下:A construction method of Camellia anthracnose genetic transformation system, its construction flow chart is as shown in Figure 7, and the steps are as follows:
1、质粒DNA的制备,步骤如下:1. Preparation of plasmid DNA, the steps are as follows:
所用质粒pBlueScriptⅡ(+)-G418-GFP由pBlueScriptⅡ(+)质粒与G418抗性表达基因(在NCBI数据库中的登录号为AAG34543.1)以及绿色荧光蛋白GFP(在NCBI数据库中的登录号为ANA76508.1)基因融合而成,具体步骤如下:The plasmid pBlueScriptⅡ(+)-G418-GFP used consists of pBlueScriptⅡ(+) plasmid and G418 resistance expression gene (accession number in NCBI database is AAG34543.1) and green fluorescent protein GFP (accession number in NCBI database is ANA76508 .1) Gene fusion, the specific steps are as follows:
采用同源重组的策略,将PCR克隆的G418抗性表达基因与单酶切XbaⅠ线性化载体pBlueScriptⅡ(+)进行重组反应,得到重组产物;按照大肠杆菌DH5α(购买于北京擎科生物科技有限公司)方法转入重组产物至DH5α感受态细胞,接入LB固体培养基(含100mg/mL氨苄青霉素),过夜培养12-16h,挑取单克隆大肠杆菌菌落置于LB液体培养基过夜培养12-16h,用质粒提取试剂盒(购买于北京擎科生物科技有限公司)的方法提取质粒pBlueScriptⅡ(+)-G418备用;进一步克隆绿色荧光蛋白基因GFP片段与单酶切KpnⅠ线性化载体pBlueScriptⅡ(+)-G418进行重组反应,得到重组产物;按照大肠杆菌DH5α(购买于北京擎科生物科技有限公司)方法转入重组产物至DH5α感受态细胞,接入LB固体培养基(含100mg/mL氨苄青霉素),过夜培养12-16h,挑取单克隆大肠杆菌菌落置于LB液体培养基过夜培养12-16h,用质粒提取试剂盒(购买于北京擎科生物科技有限公司)的方法提取质粒pBlueScriptⅡ(+)-G418-GFP备用。Using the strategy of homologous recombination, the G418 resistance expression gene cloned by PCR was recombined with the XbaⅠ linearized vector pBlueScriptⅡ(+) to obtain the recombinant product; ) method to transfer the recombinant product to DH5α competent cells, insert LB solid medium (containing 100 mg/mL ampicillin), and culture overnight for 12-16 hours, pick monoclonal Escherichia coli colonies and place them in LB liquid medium for overnight culture for 12- 16h, use the plasmid extraction kit (purchased from Beijing Qingke Biotechnology Co., Ltd.) to extract the plasmid pBlueScriptⅡ(+)-G418 for use; further clone the GFP fragment of the green fluorescent protein gene and single-digest KpnⅠ linearization vector pBlueScriptⅡ(+) -G418 was subjected to a recombination reaction to obtain a recombinant product; according to the method of Escherichia coli DH5α (purchased from Beijing Qingke Biotechnology Co., Ltd.), the recombinant product was transferred to DH5α competent cells, and inserted into LB solid medium (containing 100 mg/mL ampicillin) , cultivated overnight for 12-16 hours, picked monoclonal Escherichia coli colonies and placed them in LB liquid medium for overnight cultivation for 12-16 hours, and extracted plasmid pBlueScriptⅡ(+) with the method of plasmid extraction kit (purchased from Beijing Qingke Biotechnology Co., Ltd.) -G418-GFP spare.
2、B1)将实施例1制备得到的山茶炭疽菌原生质体,用1mL STC溶液冲洗沉淀两次,每次都置于离心机内,4℃3000rpm离心5min,得到STC溶液悬浮的原生质体溶液;2. B1) The protoplasts of Camellia anthracis prepared in Example 1 were washed and precipitated twice with 1 mL of STC solution, placed in a centrifuge each time, and centrifuged at 3000 rpm at 4° C. for 5 minutes to obtain a protoplast solution suspended in the STC solution;
B2)向500μL步骤B1)中得到的STC溶液悬浮的原生质体溶液中加入20μg步骤1中制备得到的质粒pBlueScriptⅡ(+)-G418-GFP和10μL肝素钠溶液,轻柔充分混匀,0~4℃静置30min;B2) Add 20 μg of the plasmid pBlueScriptⅡ(+)-G418-GFP prepared in
B3)逐滴加入1mL SPTC溶液,轻柔充分混匀,0~4℃静置30min;B3) Add 1mL SPTC solution dropwise, mix gently and fully, and let stand at 0-4°C for 30min;
B4)将获得的原生质体溶液悬浮于20mL再生培养基中,然后放置于恒温震荡培养箱中,26℃,转速为100rpm,培养16h;B4) Suspend the obtained protoplast solution in 20 mL of regeneration medium, and then place it in a constant temperature shaking incubator at 26° C., with a rotation speed of 100 rpm, and cultivate for 16 hours;
B5)将复苏后的原生质体与选择性培养基混合,倒成平板,放入恒温培养箱中静置黑暗培养3-5d,观察转化子生长情况。B5) Mix the revived protoplasts with the selective medium, pour them into a plate, put them into a constant temperature incubator and culture them in the dark for 3-5 days, and observe the growth of the transformants.
测试例2
在G418(150μg/mL)选择性培养基上筛选转化子,生长3-5d后,首先通过PCR方法检测G418的插入情况,再通过荧光显微镜观察转化子是否有GFP荧光。Transformants were screened on G418 (150 μg/mL) selective medium, and after growing for 3-5 days, the insertion of G418 was first detected by PCR, and then whether the transformants had GFP fluorescence was observed by fluorescence microscope.
1、转化子的PCR鉴定1. PCR identification of transformants
1.1基因组的提取:1.1 Genome extraction:
(1)从选择性培养基平板上,切下菌丝块,置于1.5mL离心管中,加入500μLDEB,组织破碎仪进行研磨;(1) Cut off the mycelium block from the selective medium plate, place it in a 1.5mL centrifuge tube, add 500μL DEB, and grind it with a tissue disruptor;
(2)4℃,12000rpm离心10min,取500μL上清置于新的1.5mL离心管中;(2) Centrifuge at 12,000 rpm for 10 min at 4°C, take 500 μL of supernatant and place in a new 1.5 mL centrifuge tube;
(3)向离心管中加入等体积异丙醇,颠倒混匀;(3) Add an equal volume of isopropanol to the centrifuge tube and invert to mix;
(4)4℃,12000rpm离心5min,弃上清;(4) Centrifuge at 12,000 rpm for 5 minutes at 4°C, discard the supernatant;
(5)向离心管中加入700μL 70%乙醇,颠倒混匀,洗去杂质;(5) Add 700 μL of 70% ethanol to the centrifuge tube, mix it upside down, and wash away impurities;
(6)4℃,12000rpm离心5min,弃上清;(6) Centrifuge at 12,000 rpm for 5 minutes at 4°C, discard the supernatant;
(7)待乙醇挥发后,向离心管中加入50μL无菌蒸馏水,溶解沉淀;(7) After the ethanol evaporates, add 50 μL sterile distilled water to the centrifuge tube to dissolve the precipitate;
(8)4℃,12000rpm离心5min,取上清于新的1.5mL离心管中,置于-20℃保存备用。(8) Centrifuge at 12,000 rpm for 5 minutes at 4°C, take the supernatant into a new 1.5mL centrifuge tube, and store at -20°C for later use.
1%琼脂糖凝胶电泳检测基因组质量,用紫外凝胶成像系统拍照并保存图片,如图4所示,其中Marker:5000bp,1,2,3:实施例8中获得的转化子,4:山茶炭疽菌LS_19;1% agarose gel electrophoresis to detect the quality of the genome, take pictures with an ultraviolet gel imaging system and save the picture, as shown in Figure 4, where Marker: 5000bp, 1, 2, 3: transformants obtained in Example 8, 4: Camellia anthracnose LS_19;
由图4可以得出:在图中1234都有条带,且总长度均大于5000bp,未见明显拖尾现象,可见基因组质量良好,提取方法可行,可以用作模板进行PCR扩增。It can be concluded from Figure 4 that in the figure 1234 have bands, and the total length is greater than 5000bp, no obvious tailing phenomenon, it can be seen that the quality of the genome is good, the extraction method is feasible, and can be used as a template for PCR amplification.
1.2目的基因PCR扩增1.2 Target gene PCR amplification
分别以转化子菌株和LS_19的总基因组DNA,pBlueScriptⅡ(+)-G418-GFP为模板对照,G418保守序列设计引物进行PCR扩增,扩增片段约400bpThe total genomic DNA of the transformant strain and LS_19, pBlueScriptⅡ(+)-G418-GFP were used as the template control, and the G418 conserved sequence was used to design primers for PCR amplification, and the amplified fragment was about 400bp
G418-F:5’-CTCTGATGCCGCCGTGTT-3’(SEQ ID NO.1)G418-F: 5'-CTCTGATGCCGCCGTGTT-3' (SEQ ID NO.1)
G418-R:5’-CCCTGATGCTCTTCGTCCA-3’(SEQ ID NO.2);G418-R: 5'-CCCTGATGCTCTTCGTCCA-3' (SEQ ID NO.2);
PCR扩增体系和程序分别如表1和表2所示:The PCR amplification system and program are shown in Table 1 and Table 2 respectively:
表1 PCR扩增体系Table 1 PCR amplification system
表2 PCR扩增程序Table 2 PCR amplification program
1%琼脂糖凝胶电泳检测PCR产物,并使用紫外凝胶成像系统观察并拍照保存,结果如图5所示,其中M:2000bp Maker;1,2:突变体转化子;3:pBlueScriptⅡ(+)-G418-GFP;4:山茶炭疽菌LS_19。The PCR products were detected by 1% agarose gel electrophoresis, and were observed and photographed using a UV gel imaging system. The results are shown in Figure 5, where M: 2000bp Maker; 1, 2: mutant transformants; 3: pBlueScriptⅡ(+ )-G418-GFP; 4: Camellia anthracis LS_19.
由图5可以看出:转化子和pBlueScriptⅡ(+)-G418-GFP条带大小在400bp左右,山茶炭疽菌LS_19无条带,可见G418片段成功插入其基因组。It can be seen from Fig. 5 that the transformant and pBlueScript II (+)-G418-GFP have a band size of about 400 bp, and the anthracnose camellia LS_19 has no band, and it can be seen that the G418 fragment has been successfully inserted into its genome.
2、荧光显微镜观察转化子的GFP荧光,无菌条件下,挑取不同部位的菌丝置于载玻片上,放置于荧光显微镜下观察并拍照保存,结果如图6所示,是菌丝样品局部显微成像,其中左图为明场,右图为绿色荧光场,标尺为10mm。2. Observe the GFP fluorescence of the transformant with a fluorescence microscope. Under sterile conditions, pick different parts of the hyphae and place them on a glass slide, place them under a fluorescence microscope for observation and take pictures for preservation. The results are shown in Figure 6, which is a mycelium sample Local microscopic imaging, in which the left image is bright field, the right image is green fluorescent field, and the scale is 10mm.
由图6可以得出:转化子的菌丝及孢子均能产生GFP荧光,表明GFP基因已成功转化至山茶炭疽菌中并获得表达。It can be concluded from FIG. 6 that both hyphae and spores of the transformant can produce GFP fluorescence, indicating that the GFP gene has been successfully transformed into and expressed in Anthracnose camellia.
由以上实施例可以得出:采用本发明中的炭疽菌原生质体制备方法制备得到的原生质体数量多,质量好,且步骤简单;同时依次为基础成功快速构建了PEG介导的炭疽菌遗传转化体系,且转化效率较高。From the above examples, it can be concluded that the number of protoplasts prepared by the method for preparing protoplasts of Bacillus anthracis in the present invention is large, the quality is good, and the steps are simple; at the same time, the genetic transformation of Bacillus anthracis mediated by PEG has been successfully constructed successively. system with high conversion efficiency.
尽管上述实施例对本发明做出了详尽的描述,但它仅仅是本发明一部分实施例,而不是全部实施例,人们还可以根据本实施例在不经创造性前提下获得其他实施例,这些实施例都属于本发明保护范围。Although the foregoing embodiment has described the present invention in detail, it is only a part of the embodiments of the present invention, rather than all embodiments, and people can also obtain other embodiments according to the present embodiment without inventive step, these embodiments All belong to the protection scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310027554.XA CN115806885A (en) | 2023-01-09 | 2023-01-09 | Preparation method of anthrax protoplast and construction method of genetic transformation system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310027554.XA CN115806885A (en) | 2023-01-09 | 2023-01-09 | Preparation method of anthrax protoplast and construction method of genetic transformation system |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115806885A true CN115806885A (en) | 2023-03-17 |
Family
ID=85487456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310027554.XA Pending CN115806885A (en) | 2023-01-09 | 2023-01-09 | Preparation method of anthrax protoplast and construction method of genetic transformation system |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115806885A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103820482A (en) * | 2014-01-26 | 2014-05-28 | 浙江大学 | Silent vector for silent fusarium endogenous genes, and application thereof |
CN105274131A (en) * | 2015-12-03 | 2016-01-27 | 江苏省农业科学院 | PEG-mediated colletotrichum gloeosporioides protoplast genetic transformation method |
CN105969671A (en) * | 2016-06-13 | 2016-09-28 | 辽宁大学 | Preparation and conversion method of inonotus obliquus protoplast |
CN105985914A (en) * | 2016-07-22 | 2016-10-05 | 北京林业大学 | Cytospora chrysosperma protoplast preparation method and prepared protoplast conversion method |
CN112824533A (en) * | 2019-11-20 | 2021-05-21 | 中国农业科学院植物保护研究所 | Method for rapidly screening compounded medicament for preventing and treating colletotrichum gloeosporioides |
CN113005136A (en) * | 2021-03-22 | 2021-06-22 | 南京林业大学 | Preparation method and application of green fluorescent protein labeled fusarium chinensis |
CN114875048A (en) * | 2022-05-05 | 2022-08-09 | 中国热带农业科学院环境与植物保护研究所 | Colletotrichum gloeosporioides succinate dehydrogenase subunit mutant, and construction method and application thereof |
-
2023
- 2023-01-09 CN CN202310027554.XA patent/CN115806885A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103820482A (en) * | 2014-01-26 | 2014-05-28 | 浙江大学 | Silent vector for silent fusarium endogenous genes, and application thereof |
CN105274131A (en) * | 2015-12-03 | 2016-01-27 | 江苏省农业科学院 | PEG-mediated colletotrichum gloeosporioides protoplast genetic transformation method |
CN105969671A (en) * | 2016-06-13 | 2016-09-28 | 辽宁大学 | Preparation and conversion method of inonotus obliquus protoplast |
CN105985914A (en) * | 2016-07-22 | 2016-10-05 | 北京林业大学 | Cytospora chrysosperma protoplast preparation method and prepared protoplast conversion method |
CN112824533A (en) * | 2019-11-20 | 2021-05-21 | 中国农业科学院植物保护研究所 | Method for rapidly screening compounded medicament for preventing and treating colletotrichum gloeosporioides |
CN113005136A (en) * | 2021-03-22 | 2021-06-22 | 南京林业大学 | Preparation method and application of green fluorescent protein labeled fusarium chinensis |
CN114875048A (en) * | 2022-05-05 | 2022-08-09 | 中国热带农业科学院环境与植物保护研究所 | Colletotrichum gloeosporioides succinate dehydrogenase subunit mutant, and construction method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103865948B (en) | A kind of method of fusarium oxysporum sesame protoplastis genetic transformation of PEG mediation | |
CN110042061B (en) | High yield gibberellin GA3Gibberella fujikuroi mutant strain and application thereof | |
CN111454924B (en) | A Trichoderma viride histone acetylase encoding gene TvGCN5 and its application | |
CN104928314B (en) | Verticillium dahliae pathogen-relatedprotein VdpdaA1 purposes | |
CN107299105A (en) | Pathogenic FonACL 3 gene of watermelon wilt pathogen, deletion DNA fragment and deletion mutant thereof and application thereof | |
CN104480085A (en) | VdUDG gene and application thereof in reducing pathogenicity of verticillium dahliae | |
CN105274131B (en) | A kind of method that PEG mediates glue spore anthrax bacteria protoplast genetic transformation | |
CN103468579B (en) | New lecanicillium bacteria genus fungi specie providing pathogenicity for diaphorina citri | |
CN110004070B (en) | A xylanase-producing Aspergillus niger genetically engineered bacterium and its construction method and application | |
CN115806885A (en) | Preparation method of anthrax protoplast and construction method of genetic transformation system | |
CN114426987B (en) | Genetic transformation method for capsicum southern blight germ | |
CN106148389A (en) | A kind of direct conversion foreign DNA enters the method that Buddhist nun's fine jade penicillium sp does not sprouts spore | |
CN105985914A (en) | Cytospora chrysosperma protoplast preparation method and prepared protoplast conversion method | |
CN104894156B (en) | Verticillium dahliae conidium yield GAP-associated protein GAP VdpdaA3 purposes | |
CN104893993B (en) | Verticillium dahliae conidium yield GAP-associated protein GAP VdpdaA2 purposes | |
CN107815459A (en) | A kind of oyster cap fungus manganese peroxidase enzyme gene and its application | |
CN116515632A (en) | Preparation method of pseudo-disc hirsutella fungus protoplast and construction method of genetic transformation system | |
CN108823234B (en) | Agrobacterium-mediated transformation of A. solani | |
CN116970494A (en) | Preparation method of cladosporium fungus protoplast and construction method of genetic transformation system | |
CN101831452B (en) | Method for efficiently expressing and producing T4 lysozyme through recombinant trichoderma reesei in inductive mode | |
CN106367360A (en) | Gene transformation method for agrobacterium-mediated paecilomyces cicadae | |
CN114958898B (en) | Establishment method and application of PEG-mediated genetic transformation system of Conchospora vulgaris | |
CN116676199A (en) | Preparation method of sporophore of fungus Didymella segeticola of genus Celastrus and construction method of genetic transformation system | |
CN104988080A (en) | Clonostachys rosea engineering strain for transforming chitinase gene, and applications thereof | |
CN108707574A (en) | One plant of yielding lipase engineering bacteria, its construction method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |